Editas Medicine, Inc.

NASDAQ: EDIT

AUGUST 24TH, 2018

Editas Medicine Overview

Editas Medicine, Inc. is a genome editing company. It focuses on
translating its genome editing technology into a novel class of
human therapeutics which enable precise and corrective molecular
modification to treat diseases. Editas Medicine, Inc. is based in
Cambridge, Massachusetts.

Next Earnings Report

Editas Medicine is expected to report earnings on November 6th,
2018. The report will be for the fiscal period ending September 30th,
2018.

Consensus Estimates & Forecast

The reported EPS for the same quarter last year was -$0.64. The
Corporate Factsheet
estimated EPS forecast for the next fiscal year is -$3.36 and is
expected to report on March 5th, 2019. Trading Symbol: EDIT

Exchange: NASDAQ

Lastest Close Price: $30.43

Insider Holdings: 5.20%

Institutional Holdings: 66.48%

Shares Outstanding: 47,675,640

Year-end Month: 12

Contact Information
Editas Medicine, Inc.
11 Hurley Street
Cambridge, MA, 2141
US Phone: 617-401-9000

© 2018 Fundamental Markets. All Rights Reserved.

FOR INFORMATIONAL PURPOSES ONLY. Fundamental Markets provides no warranty as to the accuracy, suitability, or correctness of the information contained herein. This document is not intended
to be a solicitation to buy or sell any security. All information in this report was accessed August 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except
per share amounts.
 Editas Medicine, Inc.
NASDAQ: EDIT

AUGUST 24TH, 2018

Recent Performance Historical Results Review

For the three months ended June 30th, 2018 vs June 30th, 2017, For the quarter ending March 31st, 2018 vs March 31st, 2017, Editas
Editas Medicine reported revenue of $7.37MM vs $3.10MM (up Medicine reported revenue of $3.93MM vs $0.68MM (up 475.81%) and
138.04%) and basic earnings per share -$0.82 vs -$0.65. basic earnings per share -$0.67 vs -$0.85.

Last Quarter Results
The Book value per share was 5.2987 while operating cash flow
per share was -0.4883. Editas Medicine has a current ratio of
11.7059:1. Leverage: Debt to common equity was 0.1341. Return
on equity was -12.4999% while return on assets was -7.6585%. Net
profit market as a percentage of total revenue was -787.8533%.
For the quarter ending December 31st, 2017 vs December 31st, 2016,
Editas Medicine reported revenue of $3.67MM vs $0.90MM (up
308.35%) and basic earnings per share -$0.84 vs -$1.09.
For the quarter ending September 30th, 2017 vs September 30th, 2016,
Editas Medicine reported revenue of $6.28MM vs $0.96MM (up
553.01%) and basic earnings per share -$0.64 vs -$0.59.

Latest Annual Results Contact Information

For the twelve months ended December 31st, 2017 vs December Editas Medicine, Inc.
31st, 2016, Editas Medicine reported revenue of $13.73MM vs 11 Hurley Street
$6.05MM (up 126.80%) and basic earnings per share -$2.98 vs - Cambridge, MA, 2141
$3.02. US Phone: 617-401-9000

© 2018 Fundamental Markets. All Rights Reserved.

FOR INFORMATIONAL PURPOSES ONLY. Fundamental Markets provides no warranty as to the accuracy, suitability, or correctness of the information contained herein. This document is not intended
to be a solicitation to buy or sell any security. All information in this report was accessed August 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except
per share amounts.